NewAmsterdam Pharma Company N.V. (NAMSW)

NASDAQ: NAMSW · Real-Time Price · USD · Warrants
9.55
-0.39 (-3.92%)
Jul 16, 2025, 4:00 PM - Market closed
-3.92%
Market Cap2.36B
Revenue (ttm)47.14M
Net Income (ttm)-187.36M
Shares Out 112.27M
EPS (ttm)-1.85
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume6,321
Open9.79
Previous Close9.94
Day's Range9.33 - 9.80
52-Week Range5.45 - 16.75
Beta-0.03
Analystsn/a
Price Targetn/a
Earnings DateFeb 28, 2025

About NAMSW

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in N... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Michael Davidson
Employees 68
Stock Exchange NASDAQ
Ticker Symbol NAMSW
Full Company Profile

News

There is no news available yet.